PMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PMN is not a good buy right now. The stock is in a sharp momentum spike (up ~34% regular session, ~55% pre-market) and is extremely overbought, with price stretched far above prior resistance levels and far above the latest Wall Street price target ($5). With no proprietary buy signals today and weak fundamentals (pre-revenue, widening losses), the risk/reward for an impatient buyer is unfavorable at the current ~$16.86 level.
Trend/momentum: Strong bullish momentum today (large gap/vertical move). MACD histogram is positive (0.459) and expanding, confirming upside momentum.
Overbought: RSI(6) at 87.3 signals extreme overbought conditions—often followed by pullbacks or sharp intraday reversals.
Levels: Reported pivot/resistance levels (Pivot 9.963, R1 11.649, R2 12.69) sit well below the current price (16.86), meaning PMN is trading in price-discovery above prior resistance; this is typically higher-risk to chase.
Moving averages: Converging MAs suggests a recent transition phase, but today’s move is a momentum extension rather than a clean, low-risk base breakout.
Pattern-based outlook: Similar-pattern stats indicate limited edge after the spike (next day +1.15% probability tilt, next week ~flat, next month -4.35%).
Intellectia Proprietary Trading Signals: Intellectia Proprietary Trading Signals
Strong near-term price momentum: Large upside move can attract short-term momentum traders despite lack of fresh news this week.
is far above that target, implying Wall Street valuation support is weak at current levels.
Latest quarter: 2025/Q3. Revenue: $0 (no growth base; effectively pre-revenue). Net income: -$11.58M, down ~224.84% YoY (losses widened). EPS: -$5.93, down ~176.91% YoY. Overall: Financials reflect a development-stage biotech profile with accelerating losses rather than improving operating leverage.
Recent analyst change: On 2025-11-18, Guggenheim (Eddie Hickman) reiterated a Buy but lowered the price target to $5 from $6. Wall Street pros: Ongoing confidence in PMN310’s clinical path and 2026 data catalysts. Wall Street cons: The reduced target and low absolute PT versus the current price suggest limited sell-side support for buying at today’s elevated level. Influential/political trading: No recent congress trading data available in the last 90 days.
